Resources
Life Saving Drugs Program – Fabry disease – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Fabry disease.
Life Saving Drugs Program – Fabry disease – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Fabry disease for the first time, or after a break.
New arrangements for migalastat (Galafold®) – information for prescribers
This fact sheet is for current prescribers (treating physicians) with patients requiring treatment for Fabry disease. The fact sheet explains how a treatment for this condition, migalastat (Galafold®), will be transitioning from the Life Saving Drugs Program to the PBS.
Better Renal Services Steering Committee communique – 15 July 2024
An update from the Better Renal Services Steering Committee after their meeting on 15 July 2024.
New arrangements for migalastat (Galafold®) for treatment of Fabry Disease
This fact sheet is for current and future patients with Fabry disease explaining how a treatment for this condition, migalastat (Galafold®), will be transitioning from the Life Saving Drugs Program to the PBS. The fact sheet further provides clarity on future access arrangements via the PBS.
Better Renal Services Steering Committee communique – 26 June 2024
An update from the Better Renal Services Steering Committee after their meeting on 26 June 2024.
Newborn bloodspot screening (NBS) – Progress towards consistency and expansion fact sheet
This fact sheet provides information about what NBS expansion means for families and consumers, expansion progress to date, and upcoming milestones.
Newborn bloodspot screening expansion – Readiness assessment executive summary
This publication outlines the key findings of the national readiness assessment conducted in 2023. The aim of the readiness assessment is to understand how NBS programs operate nationally. It also looks at critical factors for achieving consistency and expanding the number of conditions screened.
Review of the National Strategic Framework for chronic conditions
In September 2023, we engaged Ernst & Young to conduct a review of the National Strategic Framework for chronic conditions, its related action plans and the National Asthma Strategy 2018.
Better Renal Services Steering Committee communique – 8 May 2024
An update from the Better Renal Services Steering Committee after their meeting on 8 May 2024.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 28 June 2024
Life Saving Drugs Program (LSDP) Expert Panel agenda for the 18th meeting on 28 June 2024.
Newborn bloodspot screening (NBS) – Our national decision-making pathway fact sheet
This fact sheet provides information on the national NBS decision-making pathway, including the role of each committee in the process.
Renal facility design guidelines for remote areas
Renal facility design guidelines developed to inform the infrastructure builds of the renal dialysis units under the Better Renal Services for First Nations People Budget Measure.
Advisory Committee for the COVID-19 Response for People with Disability – Summary of outcomes 16 April 2024
This communique provides a summary of the advisory committee's meeting on 16 April 2024.
40:53
Community Dialysis Unit Expression of Interest information webinar – 18 March 2024
Webinar held on 18 March 2024, hosted by the National Aboriginal Community Controlled Health Organisation (NACCHO) and the Department of Health and Aged Care. The webinar focussed on improving access to dialysis treatments for First Nations Australians in remote communities.
Community Dialysis Unit Expression of Interest – fact sheet and FAQs
We are funding 30 dialysis units to provide life-saving health care for First Nations Australians with kidney disease. Communities are invited to self-identify dialysis need through an EOI process, as outlined by this fact sheet.
Expression of Interest form – Community Dialysis Unit
We are funding 30 dialysis units to provide life-saving health care for First Nations Australians with kidney disease. Communities are invited to self-identify dialysis need by completing this expression of interest form.
Better Renal Services Steering Committee communique – 20 February 2024
An update from the Better Renal Services Steering Committee after their meeting on 20 February 2024.
Endometriosis Progress Report 2024
This report provides an update on the progress of the National Action Plan for Endometriosis.
Advisory Committee for the COVID-19 Response for People with Disability – Summary of outcomes 13 February 2024
This communique provides a summary of the advisory committee's meeting on 13 February 2024.
56:38
Dedication ceremony and unveiling of the National Site of Recognition for Thalidomide Survivors
The National Site of Recognition for Thalidomide Survivors and their Families acknowledges the thalidomide tragedy in Australia. It serves as a lasting reminder to all Australians that the lessons of the tragedy must never be forgotten.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 16 February 2024
Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 17th meeting on 16 February 2024.
Invasive Group A Streptococcal (iGAS) Disease – CDNA National guidelines for Public Health Units
These guidelines outline Australia’s national minimum standard for surveillance, laboratory testing, case management and contact management for Invasive Group A Streptococcal (iGAS) disease.
Advisory Committee for the COVID-19 Response for People with Disability – Summary of outcomes 8 December 2023
This communique provides a summary of the advisory committee's meeting on 8 December 2023.
Better Renal Services Steering Committee communique – 4 December 2023
An update from the Better Renal Services Steering Committee after their meeting on 4 December 2023.
Date last updated: